Received May 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y012864 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | 1965045 | — |
Nurse does not report any side effects/symptoms.; patient received GARDASIL 9 outside of the recommended dosing schedule/first dose 24OCT2024/second dose 21NOV2024. Patient has returned for dose 3 today but has not yet received it.; This spontaneous report was received from a nurse referring a 33-year-old male patient. His medical history, concurrent conditions, concomitant therapies and drug reactions/allergies were not reported. On 24-Oct-2024, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) injection pre-filled syringe (batch/lot number Y012864 has been verified to be a valid batch lot number for Human Papillomavirus 9-valent Vaccine, Recombinant, expiration reported as 19-Jan-2026 but upon internal validation established as 29-May-2026), dose number 1, 0.5 mL (anatomical location and route of administration were not reported). On 21-Nov-2024, he was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) injection pre-filled syringe (batch/lot number 1965045 has been verified to be a valid batch lot number for Human Papillomavirus 9-valent Vaccine, Recombinant, expiration reported and upon internal validation established as 19-Jan-2026), dose number 2, 0.5 mL (anatomical location and route of administration were not reported) (inappropriate schedule of product administration.) Both vaccine doses were administered as prophylaxis. Patient returned for dose 3 on 01-May-2025 (reported as "today"), but he had not yet received it. Nurse did not report any side effects/symptoms (no adverse event). No additional details were provided.